M C Mabray1, R F Barajas2, J E Villanueva-Meyer2, C A Zhang3, F E Valles2, J L Rubenstein4, S Cha5. 1. From the Departments of Radiology and Biomedical Imaging (M.C.M., R.F.B., J.E.V.-M., C.A.Z., F.E.V., S.C.) marc.mabray@ucsf.edu marccm7@gmail.com. 2. From the Departments of Radiology and Biomedical Imaging (M.C.M., R.F.B., J.E.V.-M., C.A.Z., F.E.V., S.C.). 3. From the Departments of Radiology and Biomedical Imaging (M.C.M., R.F.B., J.E.V.-M., C.A.Z., F.E.V., S.C.) Epidemiology and Biostatistics (C.A.Z.). 4. Medicine Division of Hematology/Oncology (J.L.R.). 5. From the Departments of Radiology and Biomedical Imaging (M.C.M., R.F.B., J.E.V.-M., C.A.Z., F.E.V., S.C.) Neurological Surgery (S.C.), University of California San Francisco, San Francisco, California.
Abstract
BACKGROUND AND PURPOSE: CXC chemokine ligand 13 and interleukin 10 have emerged as CSF biomarkers for the diagnosis of CNS lymphoma. Our hypothesis is that the combined use of ADC, CXC chemokine ligand 13, and interleukin 10 will result in increased diagnostic performance compared with the use of ADC values alone. MATERIALS AND METHODS: Eighty-seven patients were included in this study, including 43 with CNS lymphoma and 44 without CNS lymphoma (21 metastases, 14 high-grade gliomas, 9 tumefactive demyelinating lesions) who had undergone CSF proteomic analysis and had a new enhancing mass on brain MR imaging. Average ADC was derived by contouring the contrast-enhancing tumor volume. Group means were compared via t tests for average ADC, CXC chemokine ligand 13, and interleukin 10. Receiver operating characteristic analysis was performed for each individual variable. Multiple-variable logistic regression with receiver operating characteristic analysis was performed, and the multiple-variable receiver operating characteristic was compared with single-variable receiver operating characteristics. RESULTS: The average ADC was lower and CSF CXC chemokine ligand 13 and interleukin 10 values were higher in CNS lymphoma (P < .001). Areas under the curve ranged from 0.739 to 0.832 for single-variable ROC. Multiple-variable logistic regression yielded statistically significant individual effects for all 3 variables in a combined model. Multiple-variable receiver operating characteristics (area under the curve, 0.928) demonstrated statistically significantly superior diagnostic performance compared with the use of single variables alone. CONCLUSIONS: The combined use of ADC, CSF CXC chemokine ligand 13, and interleukin 10 results in increased diagnostic performance for the diagnosis of CNS lymphoma. This finding highlights the importance of CSF analysis when the diagnosis of CNS lymphoma is considered on the basis of MR imaging.
BACKGROUND AND PURPOSE:CXC chemokine ligand 13 and interleukin 10 have emerged as CSF biomarkers for the diagnosis of CNS lymphoma. Our hypothesis is that the combined use of ADC, CXC chemokine ligand 13, and interleukin 10 will result in increased diagnostic performance compared with the use of ADC values alone. MATERIALS AND METHODS: Eighty-seven patients were included in this study, including 43 with CNS lymphoma and 44 without CNS lymphoma (21 metastases, 14 high-grade gliomas, 9 tumefactive demyelinating lesions) who had undergone CSF proteomic analysis and had a new enhancing mass on brain MR imaging. Average ADC was derived by contouring the contrast-enhancing tumor volume. Group means were compared via t tests for average ADC, CXC chemokine ligand 13, and interleukin 10. Receiver operating characteristic analysis was performed for each individual variable. Multiple-variable logistic regression with receiver operating characteristic analysis was performed, and the multiple-variable receiver operating characteristic was compared with single-variable receiver operating characteristics. RESULTS: The average ADC was lower and CSFCXC chemokine ligand 13 and interleukin 10 values were higher in CNS lymphoma (P < .001). Areas under the curve ranged from 0.739 to 0.832 for single-variable ROC. Multiple-variable logistic regression yielded statistically significant individual effects for all 3 variables in a combined model. Multiple-variable receiver operating characteristics (area under the curve, 0.928) demonstrated statistically significantly superior diagnostic performance compared with the use of single variables alone. CONCLUSIONS: The combined use of ADC, CSFCXC chemokine ligand 13, and interleukin 10 results in increased diagnostic performance for the diagnosis of CNS lymphoma. This finding highlights the importance of CSF analysis when the diagnosis of CNS lymphoma is considered on the basis of MR imaging.
Authors: F E Valles; C L Perez-Valles; S Regalado; R F Barajas; J L Rubenstein; S Cha Journal: AJNR Am J Neuroradiol Date: 2012-08-30 Impact factor: 3.825
Authors: Marius Horger; Michael Fenchel; Thomas Nägele; Robert Moehle; Claus D Claussen; Rudi Beschorner; Ulrike Ernemann Journal: AJR Am J Roentgenol Date: 2009-11 Impact factor: 3.959
Authors: P Kickingereder; F Sahm; B Wiestler; M Roethke; S Heiland; H-P Schlemmer; W Wick; A von Deimling; M Bendszus; A Radbruch Journal: AJNR Am J Neuroradiol Date: 2014-04-10 Impact factor: 3.825
Authors: James L Rubenstein; Valerie S Wong; Cigall Kadoch; Hua-Xin Gao; Ramon Barajas; Lingjing Chen; S Andrew Josephson; Brian Scott; Vanja Douglas; Mekhala Maiti; Lawrence D Kaplan; Patrick A Treseler; Soonmee Cha; Jimmy H Hwang; Paola Cinque; Jason G Cyster; Clifford Lowell Journal: Blood Date: 2013-04-09 Impact factor: 22.113
Authors: Anouk van Westrhenen; Lisanne C A Smidt; Tatjana Seute; Stefan Nierkens; Abraham C J Stork; Monique C Minnema; Tom J Snijders Journal: Br J Haematol Date: 2018-05-29 Impact factor: 6.998
Authors: Ilias Masouris; Kirsi Manz; Markus Pfirrmann; Martin Dreyling; Barbara Angele; Andreas Straube; Sigrid Langer; Marion Huber; Uwe Koedel; Louisa Von Baumgarten Journal: Front Neurol Date: 2021-03-26 Impact factor: 4.003
Authors: Ramon F Barajas; Letterio S Politi; Nicoletta Anzalone; Heiko Schöder; Christopher P Fox; Jerrold L Boxerman; Timothy J Kaufmann; C Chad Quarles; Benjamin M Ellingson; Dorothee Auer; Ovidiu C Andronesi; Andres J M Ferreri; Maciej M Mrugala; Christian Grommes; Edward A Neuwelt; Prakash Ambady; James L Rubenstein; Gerald Illerhaus; Motoo Nagane; Tracy T Batchelor; Leland S Hu Journal: Neuro Oncol Date: 2021-07-01 Impact factor: 12.300